Pulmonx Corporation is a commercial-stage medical technology company. Co. provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. We show 18 historical shares outstanding datapoints in our LUNG shares outstanding history coverage, used to compute LUNG market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LUNG market cap history over the course of time is important for investors
interested in comparing LUNG's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LUNG versus a peer is one thing; comparing
LUNG market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LUNG can fluctuate over the course of history.
With this page we aim to empower investors researching LUNG by allowing them to research the LUNG market cap history. |
Free LUNG Email Alerts:
Video: The Importance of Market Cap
